The efficacy of SBLJ23 against both wild-type (TF-1) and JAK2V617F mutant (HEL) (JAK2 mutated AML), SET2 and UKE1 cell proliferation was analyzed using the MTT assay. Here, SETD2 is linked to acute myeloid leukemia.